Innoviva (INVA) Income from Non-Controlling Interests (2017 - 2022)
Innoviva posted quarterly Income from Non-Controlling Interests of -$36.2 million for Q3 2022, down 219.76% year-on-year from $30.2 million in Q3 2021, and down 277.06% on a QoQ basis from $20.4 million in Q2 2022.
Innoviva (INVA) has 6 years of Income from Non-Controlling Interests data on file, last reported at -$36.2 million in Q3 2022.
- For the quarter ending Q3 2022, Income from Non-Controlling Interests fell 219.76% year-over-year to -$36.2 million; the trailing twelve-month figure through Sep 2023 stood at -$36.2 million (down 198.98% YoY), and the FY2022 full-year result was $6.3 million, down 93.84% from the prior year.
- Income from Non-Controlling Interests for Q3 2022 stood at -$36.2 million, down from $20.4 million in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $30.2 million in Q3 2021 and bottomed at -$36.2 million in Q3 2022.
- The 5-year median for Income from Non-Controlling Interests is $12.7 million (2019), against an average of $10.5 million.
- The widest annual swing landed in 2018, when Income from Non-Controlling Interests jumped 4128.68%; it then tumbled 219.76% in 2022.
- A 5-year view of Income from Non-Controlling Interests shows it stood at $5.5 million in 2018, then soared by 118.39% to $11.9 million in 2019, then soared by 77.23% to $21.1 million in 2020, then jumped by 43.08% to $30.2 million in 2021, then sank by 219.76% to -$36.2 million in 2022.
- The last three Income from Non-Controlling Interests figures came in at -$36.2 million (Q3 2022), $20.4 million (Q2 2022), and $22.1 million (Q1 2022), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.75 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | -36.18 Mn |
| Jun 30, 2022 | 20.43 Mn |
| Mar 31, 2022 | 22.09 Mn |
| Sep 30, 2021 | 30.21 Mn |
| Jun 30, 2021 | 21.90 Mn |
| Mar 31, 2021 | 15.57 Mn |
| Dec 31, 2020 | 21.11 Mn |
| Sep 30, 2020 | 13.40 Mn |
| Jun 30, 2020 | 21.38 Mn |
| Mar 31, 2020 | 13.52 Mn |
| Dec 31, 2019 | 11.91 Mn |
| Sep 30, 2019 | 7.24 Mn |
| Jun 30, 2019 | 8.32 Mn |
| Mar 31, 2019 | 6.23 Mn |
| Dec 31, 2018 | 5.46 Mn |
| Sep 30, 2018 | 3.08 Mn |
| Jun 30, 2018 | 1.99 Mn |
| Mar 31, 2018 | 749,000.00 |
| Dec 31, 2017 | 129,000.00 |